IL126050A - Sustained-release pharmaceuticals containing myzolastine - Google Patents

Sustained-release pharmaceuticals containing myzolastine

Info

Publication number
IL126050A
IL126050A IL12605097A IL12605097A IL126050A IL 126050 A IL126050 A IL 126050A IL 12605097 A IL12605097 A IL 12605097A IL 12605097 A IL12605097 A IL 12605097A IL 126050 A IL126050 A IL 126050A
Authority
IL
Israel
Prior art keywords
sustained
mizolastine
release pharmaceutical
formulation according
pharmaceutical formulation
Prior art date
Application number
IL12605097A
Other languages
English (en)
Hebrew (he)
Other versions
IL126050A0 (en
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of IL126050A0 publication Critical patent/IL126050A0/xx
Publication of IL126050A publication Critical patent/IL126050A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL12605097A 1996-03-04 1997-02-28 Sustained-release pharmaceuticals containing myzolastine IL126050A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9602662A FR2745500B1 (fr) 1996-03-04 1996-03-04 Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine
PCT/FR1997/000355 WO1997032584A1 (fr) 1996-03-04 1997-02-28 Formulations pharmaceutiques a liberation prolongee contenant de la mizolastine

Publications (2)

Publication Number Publication Date
IL126050A0 IL126050A0 (en) 1999-05-09
IL126050A true IL126050A (en) 2004-05-12

Family

ID=9489799

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12605097A IL126050A (en) 1996-03-04 1997-02-28 Sustained-release pharmaceuticals containing myzolastine

Country Status (35)

Country Link
US (2) US6165507A (ko)
EP (1) EP0906101B1 (ko)
JP (2) JP2000512617A (ko)
KR (1) KR100369888B1 (ko)
CN (1) CN1112929C (ko)
AR (1) AR006082A1 (ko)
AT (1) ATE219365T1 (ko)
AU (1) AU725494B2 (ko)
BG (1) BG63451B1 (ko)
BR (1) BR9707827A (ko)
CA (1) CA2247405C (ko)
CO (1) CO4780020A1 (ko)
CY (1) CY2293B1 (ko)
CZ (1) CZ291418B6 (ko)
DE (1) DE69713505T2 (ko)
DK (1) DK0906101T3 (ko)
EE (1) EE03511B1 (ko)
ES (1) ES2177942T3 (ko)
FR (1) FR2745500B1 (ko)
HK (1) HK1017999A1 (ko)
HU (1) HU227472B1 (ko)
IL (1) IL126050A (ko)
IN (1) IN187739B (ko)
NO (1) NO315841B1 (ko)
NZ (1) NZ331947A (ko)
OA (1) OA10854A (ko)
PL (1) PL189813B1 (ko)
PT (1) PT906101E (ko)
RU (1) RU2173997C2 (ko)
SK (1) SK282112B6 (ko)
TR (1) TR199801574T2 (ko)
TW (1) TW491711B (ko)
UA (1) UA49004C2 (ko)
WO (1) WO1997032584A1 (ko)
ZA (1) ZA971830B (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002087960A (ja) * 2000-07-14 2002-03-27 Toyama Chem Co Ltd 徐放性錠剤
DK1322158T3 (da) * 2000-10-02 2012-11-19 Usv Ltd Farmaceutiske præparater med langvarig frigivelse, som indeholder metformin, og fremgangsmåde til fremstilling deraf
US7052706B2 (en) 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
NZ542176A (en) * 2003-03-04 2007-12-21 Nostrum Pharmaceuticals Inc Control release formulation containing a hydrophobic material as the sustained release agent
DE10337697A1 (de) * 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
EP2564833B1 (en) 2008-07-28 2017-12-20 Takeda Pharmaceutical Company Limited Photostabilized pharmaceutical composition
JP5744412B2 (ja) * 2010-03-26 2015-07-08 テバ製薬株式会社 フロセミド製剤
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364945A (en) * 1979-12-13 1982-12-21 Whittle Barry J Nasal composition for relieving nasal distress
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4590062A (en) * 1984-04-16 1986-05-20 Tech Trade Corp. Dry direct compression compositions for controlled release dosage forms
FR2587029B1 (fr) * 1985-09-11 1987-10-30 Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
JPH0776172B2 (ja) * 1986-04-16 1995-08-16 藤沢薬品工業株式会社 マトリツクス錠
JPS62283926A (ja) * 1986-06-02 1987-12-09 Nippon Chemiphar Co Ltd 塩酸ニカルジピン持続性組成物
DE3812799A1 (de) * 1988-04-16 1989-10-26 Sanol Arznei Schwarz Gmbh Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung
JP3195391B2 (ja) * 1991-11-14 2001-08-06 エスエス製薬株式会社 徐放性トラピジル錠
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤

Also Published As

Publication number Publication date
HUP9902458A2 (hu) 2000-05-28
ZA971830B (en) 1997-09-04
NO315841B1 (no) 2003-11-03
SK121098A3 (en) 1999-01-11
JP2007182451A (ja) 2007-07-19
NO984035D0 (no) 1998-09-02
TR199801574T2 (xx) 1998-11-23
IL126050A0 (en) 1999-05-09
PL328763A1 (en) 1999-02-15
ATE219365T1 (de) 2002-07-15
FR2745500A1 (fr) 1997-09-05
CA2247405A1 (en) 1997-09-12
NO984035L (no) 1998-10-22
KR100369888B1 (ko) 2003-05-17
BG102692A (en) 1999-04-30
EP0906101A1 (fr) 1999-04-07
EP0906101B1 (fr) 2002-06-19
DE69713505D1 (de) 2002-07-25
HUP9902458A3 (en) 2002-11-28
CO4780020A1 (es) 1999-05-26
WO1997032584A1 (fr) 1997-09-12
CN1112929C (zh) 2003-07-02
BG63451B1 (bg) 2002-02-28
RU2173997C2 (ru) 2001-09-27
CY2293B1 (en) 2003-07-04
HK1017999A1 (en) 1999-12-10
PT906101E (pt) 2002-09-30
HU227472B1 (en) 2011-07-28
DE69713505T2 (de) 2003-02-13
EE9800275A (et) 1999-02-15
PL189813B1 (pl) 2005-09-30
CZ279198A3 (cs) 1999-01-13
BR9707827A (pt) 1999-07-27
CA2247405C (en) 2004-04-20
US20050202089A1 (en) 2005-09-15
NZ331947A (en) 2000-03-27
OA10854A (fr) 2003-02-05
TW491711B (en) 2002-06-21
FR2745500B1 (fr) 1998-04-03
IN187739B (ko) 2002-06-15
ES2177942T3 (es) 2002-12-16
UA49004C2 (uk) 2002-09-16
US6165507A (en) 2000-12-26
AU1930097A (en) 1997-09-22
JP2000512617A (ja) 2000-09-26
CN1212624A (zh) 1999-03-31
SK282112B6 (sk) 2001-11-06
EE03511B1 (et) 2001-10-15
AR006082A1 (es) 1999-08-11
DK0906101T3 (da) 2002-10-14
AU725494B2 (en) 2000-10-12
KR19990087387A (ko) 1999-12-27
CZ291418B6 (cs) 2003-03-12

Similar Documents

Publication Publication Date Title
EP1096937B1 (en) Sustained release ranolazine formulations
US6479496B1 (en) Methods for treating angina with ranolazine
BG64168B1 (bg) Бързоразтворима таблета на галантамин хидробромид
NZ245421A (en) Alkaline compositions of a salt of a 3,5-dihydroxy hept-6-enoic acid derivative
KR20120064141A (ko) 코팅된 정제 제형 및 방법
JP2007182451A (ja) ミゾラスチンを含有する徐放性医薬製剤
AU2019216707B2 (en) Modified release formulations of viloxazine
PL206069B1 (pl) Tabletka dwuwarstwowa zawierająca cetyryzynę i pseudoefedrynę
WO2007049868A1 (en) Stabilized pharmaceutical oral preparation containing clopidogrel bisulfate
CA2918934C (en) Combination formulation containing sustained release metformin and immediate release hmg-coa reductase inhibitor
KR20210012082A (ko) 미라베그론 및 탐스로신을 포함하는 약학 조성물
US20040105886A1 (en) Divalproex sodium tablets
MXPA03001206A (es) Preparacion solida altamente absorbible.
KR20220105505A (ko) Nep 저해제 및 arb를 포함하는 약학 조성물 및 이의 제조 방법
WO2016187595A2 (en) Oral pharmaceutical composition of methylergonovine
NZ270729A (en) Fluvastatin sodium in an alkaline carrier

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired